Affordable Access

Publisher Website

Development of drugs for Epstein-Barr virus using high-throughput in silico virtual screening.

Authors
Type
Published Article
Journal
Expert Opinion on Drug Discovery
1746-045X
Publisher
Informa UK (Taylor & Francis)
Publication Date
Volume
5
Issue
12
Pages
1189–1203
Identifiers
DOI: 10.1517/17460441.2010.524640
PMID: 22822721
Source
Medline

Abstract

Despite the impressive efficacy of nucleoside analogs for the treatment of herpesvirus lytic infection, there remain few effective treatments for latent infections. As EBV latent infection persists within and contributes to the formation of EBV-associated cancers, targeting EBV latent proteins is an unmet medical need. High-throughput in silico screening can accelerate the process of drug discovery for novel and selective agents that inhibit EBV latent infection and associated disease.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments